"The best approach for the Company and its stakeholders is the immediate exploration of a sale," Elliott Associates said in the letter, made public one day before Alexion's annual shareholder meeting. Rather than consider a sale, Alexion has been on an acquisition spree, seeking to diversify its research pipeline, deals the hedge fund criticized in the letter. Elliott said it had waited months for CEO Ludwig Hantson's "go-it-alone" approach to gain traction and is speaking out now after he announced plans to buy Portola Pharmaceuticals Inc. Alexion shares tumbled on the announcement last week, erasing approximately $1.7 billion from the company's market capitalization in one day.

Health care, one of the largest and most complex sectors, is comprised of a broad range of companies that sell medical products and services. The health care sector includes companies that sell drugs, medical devices, and insurance, as well as hospitals and health care providers. Health care stocks, as represented by the Health Care Select Sector SPDR ETF (XLV), have outperformed the broader market, providing investors with a total return of 16.3% compared to the S&P 500's total return of 5.9% over the past 12 months. In 2020, health care stocks have recouped nearly all of their losses since their March plunge while the broader market continues to suffer from the global coronavirus pandemic. The market performance numbers and the statistics in the tables in this story are as of May 20.

Alexion (ALXN) beats on earnings and sales in the first quarter of 2020 but lowers view due to the ongoing pandemic.

If other factors are constant while comparing stocks, the one with a higher earnings yield has the potential to provide comparatively greater returns.

Alexion (ALXN) delivered earnings and revenue surprises of 19.26% and 6.98%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Mastercard and Booking make the list Continue reading...

Alexion Reports First Quarter 2020 Results

Teva Pharmaceuticals is sticking with its financial forecasts, while some of its counterparts have not.

The company cut its guidance for the full fiscal year, saying it now expects revenue of between $5.2 billion and $5.3 billion.

ALXN earnings call for the period ending March 31, 2020.

Vesa Equity Investments disclosed a large stake in Macy’s, and plans to have talks with management and other shareholders

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]

Alexion Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Alexion Pharmaceuticals topped first-quarter estimates Wednesday, but the biotech giant trimmed its full-year outlook amid the coronavirus pandemic. ALXN stock slipped in early action.

Alexion Announces Upcoming Data Presentations at the Virtual 25th Congress of the European Hematology Association

Alexion Pharmaceuticals pledged to buy Portola Pharmaceuticals on Tuesday in a deal that combines two blood disease-focused biotech companies. Alexion stock slipped, but Portola stock flew.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q1 earnings releases amid the coronavirus crisis.

Elliott Advisors says most recent acquisition is an example of its questionable strategy Continue reading...

Q1 2020 Alexion Pharmaceuticals Inc Earnings Call